Published

07 Jan 26

Updated

07 Aug 26

Views

15

Not Invested

Microba Life SciencesMAP

Fair Value

AU$0.12

Share price07 Aug

AU$0.04958.6% undervalued

Loading

1Y-46.74%

7D2.08%

Microbiome Diagnostics And Therapeutics Will Reshape Chronic Disease Management Over The Long Term

AN

AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

07 Jan 26

Updated

07 Aug 26

Views

15

Not Invested

Shared on 07 Aug 26

Fair value Increased 41%

MAP: Recent Equity Raising Will Support Future Upside Potential

Analysts have lifted their fair value estimate for Microba Life Sciences from A$0.08 to A$0.12, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What’s in the News for Microba Life Sciences Microba Life Sciences completed a follow on equity offering of A$5.000212 million in ordinary shares, including 91,344,455 securities at A$0.05 with a A$0.003 discount per security and attached options, and a further 8,659,785 securities on the same terms, with the transaction described as a subsequent direct listing.

0 views

Shared on 24 Jul 26

Fair value Decreased 61%

MAP: Capital Raising Plans Will Support Future Upside Potential

Microba Life Sciences lines up shareholder votes for new fundraising, including new shares and bonus options, to keep building its business. At the same time, expectations for what the company could be worth come down, so the upside case now depends more on what this new funding enables next.

3 views

Fair Value vs Share Price

AU$0.12

vs AU$0.04958.6% undervalued

45%

Revenue growth

4.9%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Microba Life Sciences

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Excellent balance sheet with slight risk.

Market capAU$35.1m

PB1.2x

Estimated Growth32.6%

Dividend YieldN/A

CEO & management

Luke Reid

CEO

1.6yrs

CEO Tenure

Provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland.